- Completion of third product license of Ram Shima ? Trukshima ...?Consultation on distribution plan and launching date - Trastuzumab is the first biosimilar to be approved by Australia. [2018?years?8?Mon?2?days?]?Celltrion recent Australian sikyak destination?(TGA, Therapeutic Goods Administration)?breast cancer and gastric cancer therapeutic antibody biosimilar for from?Her jyuma?(?ingredient name?:?trastuzumab?),?for?he announces a marketing authorization?. Trastuzumab?(Trastuzumab)?first received marketing authorization of biosimilars in Australia?"?Huh jyuma?'?has early breast cancer and local progressive?,?metastatic breast cancer?,?the anti-cancer antibody biosimilar used in the treatment of advanced gastric cancer?.?Original medicines are allowed jyuma Genentech?(Genentech)?to develop and Roche?(Roche)?to sell?'?Herceptin?'?is?.   Herjuma's original drug?sales in?Australia are about?134?billion won?^[1]?a year?.?Celltrion is discussing Celltrion Healthcare and Hurjuma's distribution channels in Australia and plans to?launch a strategic launch?in light?of?local market conditions?.   Celltrion?entered the Australian market with?Pfizer, a distribution partner?, in?August?2015?,?licensed by?Lamshima?in Australia?.?In?April?, the company obtained approval from the Australian Food and Drug Administration for its second product, an anticancer antibody for the treatment of blood cancer, Biosimilar Trochesima?.   Celltrion officials?"?will do my best to make rapid market penetration of the cancer patients in Australia so that they can enjoy the benefits of high-quality biopharmaceutical products at a reasonable price?,"?he said?.